Janet Woodcock, MD
PersonMentions
2
Relationships
1
Events
1
Documents
1
Relationship Network
Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons.
Drag nodes to reposition. Node size indicates connection count.
Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak).
Use legend and help buttons in the graph for more guidance.
Event Timeline
Interactive Timeline: Hover over events to see details. Events are arranged chronologically and alternate between top and bottom for better visibility.
1 total relationships
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
FDA
|
Employment |
5
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| 2013-11-14 | N/A | Publication of 'Expediting Drug Development – The FDA’s New Breakthrough Therapy Designation' in ... | N/A | View |
HOUSE_OVERSIGHT_024018.jpg
This document appears to be a page from a confidential investment prospectus for a fund named 'NLV-III' (likely New Leaf Ventures). It outlines the investment strategy, focusing on biopharmaceutical trends such as FDA 'breakthrough therapy' designations and 'information convergence' in healthcare to reduce costs. The document cites a 2013 editorial by FDA Director Janet Woodcock and notes the evolving commercial models of large pharmaceutical companies.
Investment prospectus / fund strategy document
2025-11-19
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity